miR‑205‑5p downregulation decreases gemcitabine sensitivity of breast cancer cells via ERp29 upregulation

Ma,Changpo; Shi,Xuejun; Guo,Wenchao; Feng,Fukai; Wang,Guangshun

doi:10.3892/etm.2019.7962

miR‑205‑5p downregulation decreases gemcitabine sensitivity of breast cancer cells via ERp29 upregulation

Authors:
- Changpo Ma
- Xuejun Shi
- Wenchao Guo
- Fukai Feng
- Guangshun Wang
View Affiliations

Affiliations: Thoracic Surgery Department, Tianjin Baodi People's Hospital, Tianjin 301800, P.R. China
Published online on: August 30, 2019 https://doi.org/10.3892/etm.2019.7962
Pages: 3525-3533
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common cancer in women worldwide, and the incidence and mortality rates are increasing every year. Dysregulation of microRNAs (miRNAs or miRs) is an important step in the initiation and development of breast cancer. Previous studies demonstrated that miR‑205‑5p is closely associated with occurrence and development of breast cancer; however, underlying mechanisms remain unclear. In the present study, reverse transcription‑quantitative polymerase chain reaction assays were used to analyze miR‑195‑5p and endoplasmic reticulum protein 29 (ERp29) levels in breast cancer and matched normal tissues. Western blot analysis was performed to analyze ERp29 and heat shock protein 27 (HSP27) protein expression levels. Cell viability, flow cytometry and luciferase reporter assay were used to examine cell proliferation, apoptosis and direct miRNA‑mRNA binding, respectively. The results revealed that miR‑205‑5p expression in breast cancer tissues and cell lines was decreased compared with normal tissues and a normal cell line. Overexpression of miR‑205‑5p significantly augmented cytotoxicity effects of gemcitabine treatment in MDA‑MB‑231 and BT549 cells. It was observed that miR‑205‑5p negatively regulated ERp29 expression in breast cancer cells. Dual luciferase assays confirmed that ERp29 was a target of miR‑205‑5p in breast cancer cells. Additionally, following the established gemcitabine‑resistant MDA‑MB‑231 cells (MDA‑MB‑231/GEM), ERp29 and HSP27 expression was upregulated and miR‑205‑5p was downregulated compared with parental cells. Overexpression of miR‑205‑5p reversed gemcitabine resistance in MDA‑MB‑231/GEM cells. In conclusion, the present study indicated that miR‑205‑5p may inhibit gemcitabine resistance in breast cancer cells via inhibition of ERp29 expression.

View Figures

View References

1	Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I and Walsh G; IMPACT Trialists Group, : Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 23:5108–5116. 2005. View Article : Google Scholar : PubMed/NCBI
2	Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B and Winer EP: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
3	Tripathy D: Gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer. 1 (Suppl):S8–S11. 2002. View Article : Google Scholar
4	Spielmann M: Single-agent gemcitabine as first line therpy in patient with metastatic breast cancer. Oncology. 62:2–8. 2011.
5	Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J and Melemed A: Gemcitabin as first-line therapy in patient with metastatic breast cancer: A phase II trail. Oncology. 62:2–8. 2002. View Article : Google Scholar : PubMed/NCBI
6	CACA-CBCS, Chinese Anti-Cancer Association, Committee of Breast Cancer Society, . Guidelines for diagnosis and treatment of breast cancer in China (2017). China Oncol. 27:1007–3639. 2017.
7	Vincenzi B, Santini D, Spoto S, Finolezzi E, D'Angelillo RM, La Cesa A and Tonini G: The antineoplastic treatment in the elderly. Clin Ter. 153:207–215. 2002.PubMed/NCBI
8	Wu ZH, Lin C, Liu MM, Zhang J, Tao Z and Hu XC: Src inhibition can synergize with gemcitabine and reverse resistance in triple negative breast cancer cells via the AKT/c-Jun pathway. PLoS One. 11:e01692302016. View Article : Google Scholar : PubMed/NCBI
9	Zhang D and Richardson DR: Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer. Int J Biochem Cell Biol. 43:33–36. 2011. View Article : Google Scholar : PubMed/NCBI
10	Martin C, Ardizzoni A and Rosso R: Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano). 9:297–303. 1997.PubMed/NCBI
11	Wu P, Zhang H, Qi L, Tang Q, Tang Y, Xie Z, Lv Y, Zhao S and Jiang W: Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncol Rep. 27:987–994. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhang D and Putti TC: Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. Exp Cell Res Dec. 316:3522–3531. 2010. View Article : Google Scholar
13	Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 31:1345–1350. 2007.PubMed/NCBI
14	Zhang Y, Hu Y, Wang JL, Yao H, Wang H, Liang L, Li C, Shi H, Chen Y, Fang JY and Xu J: Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp. Oncogene. 36:5473–5483. 2017. View Article : Google Scholar : PubMed/NCBI
15	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
16	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
17	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
18	Calin GA and Konopleva M: Small gene, big number, many effects. Blood. 120:240–241. 2012. View Article : Google Scholar : PubMed/NCBI
19	Farmer DT, Shariat N, Park CY, Liu HJ, Mavropoulos A and McManus MT: Partially penetrant postnatal lethality of an epithelial specific MicroRNA in a mouse knockout. PLoS One. 8:e766342013. View Article : Google Scholar : PubMed/NCBI
20	Greene SB, Gunaratne PH, Hammond SM and Rosen JM: A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci. 123:606–618. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
22	De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, D'Agostino D, Capone E, Stassi G, Todaro M, et al: MIR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death. 6:e18232015. View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Qi L, Wu P, Zhang X, Qiu Y, Jiang W, Huang D, Liu Y, Tan P and Tian Y: Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines. Med Oncol. 29:721–728. 2012. View Article : Google Scholar : PubMed/NCBI
25	Dyawanapelly S, Kumar A and Chourasia MK: Lessons learned from gemcitabine: Impact of therapeutic carrier systems and Gemcitabine's drug conjugates on cancer therapy. Crit Rev Ther Drug Carrier Syst. 34:63–96. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ying SY, Chang DC and Lin SL: The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Mol Biotechnol. 38:257–268. 2008. View Article : Google Scholar : PubMed/NCBI
27	Lou W, Liu J, Gao Y, Zhong G, Ding B, Xu L and Fan W: MicroRNA regulation of liver cancer stem cells. Am J Cancer Res. 8:1126–1141. 2018.PubMed/NCBI
28	Zhang W, Liu J and Wang G: The role of microRNAs in human breast cancer progression. Tumour Biol. 35:6235–6244. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018. View Article : Google Scholar : PubMed/NCBI
30	Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
31	Li L and Li S: miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1. Oncol Lett. 16:1715–1721. 2018.PubMed/NCBI
32	Okamoto K, Miyoshi K and Murawaki Y: miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 8:e776232013. View Article : Google Scholar : PubMed/NCBI
33	Bambang IF, Lee YK, Richardson DR and Zhang D: Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells. Oncogene. 32:1240–1251. 2013. View Article : Google Scholar : PubMed/NCBI
34	Deng YJ, Tang N, Liu C, Zhang JY, An SL, Peng YL, Ma LL, Li GQ, Jiang Q, Hu CT, et al: CLIC4, ERp29, and Smac/DIABLO derived from metastatic cancer stem-like cells stratify prognostic risks of colorectal cancer. Clin Cancer Res. 20:3809–3817. 2014. View Article : Google Scholar : PubMed/NCBI
35	Bambang IF, Xu S, Zhou J, Salto-Tellez M, Sethi SK and Zhang D: Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells. Lab Invest. 89:1229–1242. 2009. View Article : Google Scholar : PubMed/NCBI
36	Shnyder SD, Mangum JE and Hubbard MJ: Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer. J Proteome Res. 7:3364–3372. 2008. View Article : Google Scholar : PubMed/NCBI
37	Farmaki E, Mkrtchian S, Papazian I, Papavassiliou AG and Kiaris H: ERp29 regulates response to doxorubicin by a PERK-mediated mechanism. Biochim Biophys Acta. 1813:1165–1171. 2011. View Article : Google Scholar : PubMed/NCBI